Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Head & Neck 2Gynecologic 2Genitourinary 2Dermatologic 2Lymphoid 1Breast 1

Conditions

Prostatic Neoplasms 383Carcinoma, Renal Cell 210Urinary Bladder Neoplasms 117Carcinoma, Non-Small-Cell Lung 99Melanoma 78Kidney Neoplasms 74Carcinoma, Transitional Cell 73Neoplasm Metastasis 72Ovarian Neoplasms 71Breast Neoplasms 69Neoplasms 64Colorectal Neoplasms 59Squamous Cell Carcinoma of Head and Neck 50Stomach Neoplasms 49Uterine Cervical Neoplasms 44Pancreatic Neoplasms 44Triple Negative Breast Neoplasms 39Lung Neoplasms 35Esophageal Neoplasms 32Non-Muscle Invasive Bladder Neoplasms 31Endometrial Neoplasms 30Carcinoma, Hepatocellular 29Sarcoma 28Small Cell Lung Carcinoma 25Head and Neck Neoplasms 25Colonic Neoplasms 19Wilms Tumor 15Metastatic Castration-resistant Prostate Cancer 14Glioblastoma 14Carcinoma, Merkel Cell 14

Interventions

pembrolizumab 1epacadostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Microsatellite Instability × Genitourinary × Clear all
NCT05592626 2025-07-09

START-001

Marengo Therapeutics, Inc.

Phase 1/2 Recruiting
365 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Abdominal Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Genital Neoplasms, Female, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Nasopharyngeal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms, Urogenital Neoplasms, Vulvar Diseases, Vulvar Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Epstein-Barr Virus Infections, Papillomavirus Infections, Microsatellite Instability, Small Cell Lung Carcinoma

NCT02178722 2022-02-14

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Incyte Corporation

Phase 1/2 Completed
444 enrolled 19 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Microsatellite Instability, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡